Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts

Transplantation

Volumn 62, Issue 7, 1996, Pages 1018-1023

  Davis, Elizabeth A ^a   Pruitt, Scott K ^b   Greene, Peter S ^a   Ibrahim, Sherif ^a   Lam, Tuan T ^a   Levin, James L ^c   Baldwin III, William M ^a   Sanfilippo, Fred ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c T Cell Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BRL 55730; COMPLEMENT; COMPLEMENT RECEPTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; IMMUNOSUPPRESSIVE TREATMENT; INTRAARTERIAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NEWBORN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SWINE; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; COMPLEMENT INACTIVATOR PROTEINS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; MACACA FASCICULARIS; MALE; RECEPTORS, COMPLEMENT; STEROIDS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029851463     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00022     Document Type: Article

References (25)

1. Sandrin SS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal (αl-3) Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
2. Lachman PJ. The control of homologous lysis. Immunol Today 1991; 12: 312.
3. Shin ML, Hansch G, Hu VW, Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol 1986; 136: 1777.
4. Rollins S, Zhao J, Ninomiya H, Sims P. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991; 146: 2345.
5. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423.
6. White DJG. hDAF transgenic pig organs: are they concordant for human transplantation? Xeno 1996; 4: 50.
7. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
8. Pruitt SK, Bollinger RR, Collins BH, et al. Continuous complement (C) inhibition using soluble C receptor type 1 (sCR1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts. Transplant Proc 1996; 26: 756.
9. Whaley K. Measurement of complement. In: Whaley K, ed. Methods in complement for clinical immunologists. Edinburgh: Churchill Livingstone, 1985: 77.
10. Galili U, Tibell A, Samuelsson B, Rydberg L, Groth CG. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995; 59: 1549.
11. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
12. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480.
13. Inverardi L, Pardi R. Early events in cell-mediated recognition of vascularised xenografts: cooperative interactions between selected lymphocyte subsets and natural antibodies. Immunol Rev 1994; 141: 71.
14. Fryer JP, Leventhal JR, Dalmasso AP, et al. Beyond hyperacute rejection: accelerated rejection in a discordant xenograft model by adoptive transfer of specific cell subsets. Transplantation 1995; 59: 171.
15. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146.
16. Leventhal JR, Sakiyalak P, Witson J, et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 1994; 57: 974.
17. Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection. Immunol Today 1996; 17: 379.
18. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. Transplantation of discordant xenografts: a challenge revisited. Immunol Today 1996; 17: 373.
19. Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58: 1059.
20. Bach FH, Robson SC, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol Rev 1994; 141: 5.
21. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation 1996; 62: 303.
22. Day JD, Hutchins GM, Byrne BJ, et al. Transplant related accelerated arteriosclerosis in heart transplant recipients: the central role of endothelial injury. In: Solez K, Racusen LC, Billingham M, eds. Solid organ transplant rejection-mechanisms, pathology, and diagnosis. New York: Marcel Dekker, 1995: 107.
23. Opelz G, Wujciak K. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplantation Study. N Engl J Med 1994; 330: 816.
24. Ratkovec RM, Hammond EH, O'Connell JB, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch: preliminary results with plasmapheresis. Transplantation 1992; 54: 651.
25. D'Alessandro AM, Sollinger HW, Knechtle SJ, et al. Living related and unrelated donors for kidney transplantation: a 28-year experience. Ann Surg 1995; 222: 353.